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Pancreatic ductal cancer (PC) is difficult to treat, with most
patients surgically unresectable at the time of diagnosis. Moreover,
even for those who are resected, the risk of recurrence is exceed-
ingly high, and the outcome remains unsatisfactory. The prognosis
of unresectable PC patients is also extremely poor, mainly because
currently available chemotherapeutic agents are largely ineffec-
tive. Accordingly, there is a clear need for new, effective agents in
the management of PC. New agents with unique mechanisms of
action are attractive candidates for clinical trials with the hope
that their anti-tumour activity will be translated into long-term
survival.
Docetaxel, which is a member of the family of taxanes, is one of
the most important new chemotherapeutic agents to be found in
recent years (Bissett et al, 1993; Cortes and Pazdur, 1995;
Eisenhauer, 1995). It acts by enhancing microtubule assembly and
inhibiting tubulin depolymerization, thus disrupting cell division
(Schiff et al, 1979; Guéritte-Voegelein et al, 1991; Rowinsky and
Donehower, 1995). This mechanism of action is unlike any of the
standard cytotoxic agents, and therefore docetaxel has the poten-
tial for activity against human solid tumours, including PC, that
are refractory to established anti-cancer agents. In fact, two
phase II trials of advanced PC, which were conducted in France
and the USA, have reported high response rates (20%) and
relatively longer survival with the drug administered at
100 mg m22 over a 1-h period (Rougie et al, 1994; Abbruzzese
et al, 1995).
We report here our results of a cooperative phase II study of
moderate-dose (60 mg m–2) docetaxel in Japanese patients with
previously untreated metastatic PC. In our country, the recom-
mended dose for phase II trials of docetaxel is 60 mg m22 infused
over a 1-h session, because a Japanese phase I trial determined
the maximum-tolerated dose (MTD) to be 70–90 mg m22, with
leucocytopenia as the dose-limiting toxicity (Taguchi et al., 1994).
PATIENTS AND METHODS
Patients
Patients eligible for study entry had metastatic PC for which they
had not received any treatment. Each patient was required to meet
the following eligibility criteria: a performance status (PS) of 0–2;
15–74 years of age; at least one bidimensionally measurable
tumour; estimated life expectancy ³ 2 months after study entry;
adequate renal function (normal serum creatinine and blood urea
nitrogen levels); adequate liver function (total bilirubin level
≤ 1.5 mg dl21 (or ≤ 3.0 mg dl21 after biliary drainage if the patient
had obstructive jaundice); adequate serum transaminases (GOT,
GPT) levels ≤ 2 times upper normal limit (UNL) (or ≤ 3 times
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UNL in the patients with liver metastases and/or obstructive jaun-
dice) and serum alkaline phosphatase ≤ 1.5 times UNL (or ≤ 2.5
times UNL in the patients with liver metastases and/or obstructive
jaundice); adequate bone marrow reserve (white blood cell count
³ 4000 mm3 and ≤ 10 000 mm3, neutrophil count ³ 2000 mm3,
platelet count ³ 100 000 mm3, and haemoglobin level ³ 9.5 g
dl21); and written informed consent.
The exclusion criteria were as follows: active infection; severe
heart disease; interstitial pneumonitis or pulmonary fibrosis; ³
grade 2 peripheral neuropathy by the Japan Society for Cancer
Therapy (JSCT) toxicity criteria (Japan Society for Cancer
Therapy, 1993); known metastases of the central nervous system;
active concomitant malignancy; pregnant and lactating females;
females of childbearing age unless using effective contraception;
concurrent treatment with corticosteroids; history of drug-
hypersensitivity; pleural or pericardial effusion that required
drainage; peripheral oedema; other serious medical conditions.
The number of patients to be enrolled was planned using a
modified multi-stage Fleming design based on the assumptions
that expected response rate of docetaxel was 15%, response rate to
be judged no activity was 5%, a error was 5% (one-tailed) and
b error was 10% (Fleming, 1982; Simon, 1989). In case of no
response, the number of 19 patients provides that the lower limit of
95% confidence interval (CI) is ≤ 15%. However, interim analysis
was planned to be done when 20–25 patients were enrolled,
because some eligible patients often had not been evaluable for the
activity in clinical trials of metastatic PC. If none of the first 20–25
patients had a partial or complete response, the trial was to be
ended. If a major objective response was detected in any of the
first 20–25 patients studied, an additional 20–25 patients were to
be studied in a second stage of accrual to estimate more precisely
the actual response rate.
Treatments
Patients were admitted to hospitals during the chemotherapy
courses. Docetaxel was supplied by Rhone-Poulenc Rorer
Pharmaceuticals Inc., Antony, France, in a concentrated sterile vial
that contained 80 mg of the drug in 2 ml of polysorbate 80. The
starting dose of 60 mg m22 was diluted in 250–500 ml of 5%
glucose or 0.9% saline, and was infused over a 1- to 2-h period. No
routine premedication for hypersensitivity reactions was given,
and there was no routine prophylactic administration of anti-
emetics or granulocyte colony-stimulating factors. The treatment
was repeated every 3–4 weeks, provided the patient had suffi-
ciently recovered from toxicity, and was continued until there was
evidence of disease progression or unacceptable toxicity.
The dose of docetaxel was adjusted according to haematological
and other toxicities observed. Patients without ³ grade 3 toxicity
during the first course could receive 70 mg m22 in subsequent
courses. Patients who experienced grade 4 leucocytopenia or
neutropenia that lasted ³ 5 days, or had a treatment delay of
. 2 weeks due to incomplete recovery from toxicity, received
50 mg m22 in subsequent courses. The treatment was stopped
when ³ grade 3 toxicities other than haematological, nausea/
vomiting, anorexia, malaise/fatigue, or alopecia occurred.
When hypersensitivity reactions occurred, the docetaxel admin-
istration was stopped, and corticosteroids and antihistamines were
given. Patients who experienced hypersensitivity reactions were
pretreated with these drugs in subsequent courses. Patients who
experienced ³ grade 2 nausea/vomiting were pretreated with
anti-emetics in subsequent courses. With respect to leucocytopenia
or neutropenia, lenograstim (Neutrogin; Chugai Pharmaceuticals
Inc., Tokyo, Japan) was administered subcutaneously when grade
4 toxicity or grade 3 toxicity with fever occurred.
Response and toxicity evaluation
The primary end point of this study was to evaluate the activity
and toxicity of docetaxel in metastatic PC. The anti-tumour
response was assessed at least every 3–4 weeks. In this study, sizes
of metastatic lesions were measured to evaluate objective tumour
response to docetaxel; however, pancreatic masses were not
considered to be measurable but only assessable, because imaging
modalities including ultrasonography (US) and computerized
tomography (CT) may be insufficient to accurately determine the
tumour size of pancreatic masses. The best overall response (best
response category achieved between the start of docetaxel treat-
ment and the onset of progression) was recorded for each patient.
The duration of response (dated from study entry), time to progres-
sion (dated from study entry), and duration of survival (dated from
study entry) were also calculated by the Kaplan–Meier method.
All responses were strictly judged by extramural review.
The clinical response to docetaxel treatment was evaluated by
PS and pain. PS was recorded weekly by physicians, and patients
with a PS of 1 or 2 were defined as eligible, because a patient with
a PS of 0 did not have potential to improve. Pain was evaluated
by measuring changes from the baseline in pain intensity and
morphine consumption. Patients who met at least one of the
following criteria were defined as eligible for the evaluation of
pain: (1) baseline pain intensity of ³ 20 (out of 100) as measured
by the pain assessment card, and (2) baseline morphine consump-
tion of ³ 10 mg day21. Each of the eligible patients recorded pain
intensity on a pain assessment card every 2 weeks.
We used the JSCT criteria, which are fundamentally similar to
the World Health Organization (WHO) criteria (Miller et al, 1981),
for evaluating the responses and the toxic effects. A monitoring
committee was arranged independently to assess the evaluation of
efficacy and safety in the study.
This trial was designed in accordance with Japanese guidelines
for the clinical evaluation of anti-neoplastic drugs (The Ministry
of Health and Welfare, 1991), and was performed after the
approval of the investigational review board of each hospital was
given.
RESULTS
Patients
Twenty-two patients were enrolled in the study from 12 hospitals
across Japan between October 1995 and December 1996
(Registration Office, Japanese Society for Cancer Chemotherapy).
One patient was retrospectively found to be ineligible (he had
acinar cell carcinoma rather than adenocarcinoma) and was
excluded from the analysis. Thus, 21 metastatic PC patients were
eligible and evaluable for both the activity and toxicity. The
diagnosis of PC was confirmed by histological examination in
15 patients and, in the remaining six patients, it was based on
typical radiographic findings of PC. However, in three of these six
patients, the diagnosis of PC was confirmed histologically by
autopsy.
The baseline characteristics of the 21 eligible patients are
summarized in Table 1. There were 11 males and ten females with440 S Okada et al
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a median age of 58 years (range 43–70). Eleven patients (52%) had
symptomatic disease (PS 1 or 2). One patient had undergone a
pancreatectomy with intraoperative radiotherapy, and another
patient had received previous radiation therapy to the pancreatic
mass. Before chemotherapy, three patients underwent biliary
drainage for obstructive jaundice. Six patients (29%) showed
normal liver function, and the remaining 15 (71%) had liver
dysfunction. Seventeen patients (81%) had liver metastasis.
Among them, 16 had liver involvement of less than 25% of the
entire liver, and the remaining one patient had involvement of
25–50%. Fifteen patients (71%) had one metastatic site and six
(29%) had two metastatic sites.
Treatments
The 21 patients eligible for the study were given a total of 45
courses, with a median of two courses each (range 1–4). The dose
of docetaxel was modified for six patients; dose reduction to
50 mg m22 was necessary in two of the three courses as a result of
myelosuppression, and dose escalation to 70 mg m22 was done in
four of the eight courses because of good tolerability during the
prior course. The median cumulative dose of docetaxel received
was 120 mg m22, with a range of 60–270 mg m22. The reasons for
treatment discontinuation were: disease progression (18 patients;
86%), patient’s refusal of treatment (one patient; 5%) and toxicity
(two patients – one early death due to neutropenic sepsis and one
neurosensory disorder; 9%). After docetaxel treatment, six patients
received systemic chemotherapy, one radiotherapy for pancreatic
mass and one chemoradiation for pancreatic mass. However, no
patient achieved an objective tumour response. The other 13
patients underwent only the best supportive care after docetaxel
treatment.
During the study, five patients may have received about
10% overdose due to an inadequate preparation of docetaxel.
Therefore, for the statistical analysis, two patient populations were
defined: the intent-to-treat population which included all eligible
patients (21 patients); and the population which included the
eligible patients who received docetaxel at the scheduled dose
(16 patients).
Response
Although the response could not be determined in one patient due
to an early death on day 8 of the first course, no objective response
was observed, giving an overall response rate of 0% (95% CI,
0–15%). Seven (33%) of the eligible patients showed no change
(NC) with a median duration from study entry of 98 days (range
50–168 days). Among these NC patients, one patient achieved a
61% decrease in the size of liver metastasis, but this condition did
not last for 4 weeks. The remaining 13 (62%) patients showed
progressive disease (PD). The patients who achieved NC received
a median of three courses (range 2–4), and those with PD
received a median of two courses (range 1–3).
Progression of disease was seen in 20 (95%) of the 21 patients,
and the remaining one patient was not evaluable for time to
progression because of an early death. The median time to progres-
sion was 36 days (range 14–168 days). All but two patients died,
with the median survival time of 118 days (95% CI, 105–158
days). Two patients had survived for more than 1 year (6071 and
5961 days) at the time of analysis. Among the 16 patients who
received docetaxel at the scheduled dose, the median time to
progression was 41 days (range 16–168 days), with the median
survival time of 109 days (95% CI, 99–131 days).
With regard to clinical response, one (9%) of the 11 eligible
patients with a PS of 1 or 2 experienced an improvement in PS.
The responder had a PS of 1 before chemotherapy, and his general
condition improved after three courses of docetaxel, i.e. a PS of 0
sustained for 6 weeks. Among the 13 eligible patients in the evalu-
ation of pain, ten had an increase from baseline and the remaining
three showed no remarkable change in morphine consumption.
One (8%) of the three patients with no increase in morphine
consumption achieved an improvement of ³ 50% from baseline in
pain intensity for 8 weeks.
Toxicity
The haematological toxicity of docetaxel is summarized in Table
2. All but one patient were assessed for toxicity. One patient died
of neutropenic sepsis on day 8 of the first course, before the evalu-
ation of toxicity was complete. The docetaxel therapy was gener-
ally well-tolerated, with haematological toxicity, most notably
reversible neutropenia, being the most common severe toxicity
of docetaxel on this schedule. Grade 3–4 leucocytopenia and
neutropenia occurred in 14 (67%) and 18 (86%) of the patients
respectively. Grade 4 leucocytopenia occurred in two (10%)
patients and two (4%) courses, and neutropenia occurred in 11
(52%) patients and 16 (36%) courses. However, the leucocyto-
penia and neutropenia were brief and reversible, although these
patients received lenograstim; the median time to the nadir of the
neutropenia was 8 days, and the median time from the nadir to
Table 1 Profile of the metastatic pancreatic cancer patient population
Characteristics No. %
No. of patients 21
Gender
Male 11 52
Female 10 48
Age, years
Median 58
Range 43–70
ECOGa performance status
01 0 4 8
17 3 3
24 1 9
Prior therapy
Pancreatectomy 1 5
Palliative surgery 3 14
Radiotherapy 2 10
Liver dysfunction 15 71
Sites of metastases
Liver 17 81
Lymph nodes 8 38
Lung 1 5
Ovary 1 5
No. of metastatic sites
11 5 7 1
26 2 9
No. of treatment courses
17 3 3
27 3 3
34 1 9
43 1 4
aECOG: Eastern Cooperative Oncology GroupPhase II study of docetaxel in pancreatic cancer 441
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recovery (³ 2000 ml) was 8 days. Febrile episodes occurred in 14
(67%) patients and a neutropenic fever, defined as fever (. 388C)
concomitant with grade 4 neutropenia, occurred in six (29%)
patients and six (13%) courses. Thrombocytopenia and anaemia
were infrequent and mild. No cumulative tendency of myelosup-
pression was noted as the treatment courses continued.
The non-haematological toxicities of docetaxel in this study,
summarized in Table 2, were generally mild and well-tolerated.
Nausea/vomiting, anorexia, malaise/fatigue and alopecia were the
most common non-haematological toxicities. Although the
majority of these events were mild, it was ³ grade 3 in about one-
third of the patients. Other grade 3 toxicities consisted of liver
function abnormalities, sensory neuropathy and proteinuria.
Diarrhoea was fairly common, as was skin rash, but these were
both mild and transient. Despite having received no prophylactic
premedication, no patient experienced hypersensitivity reactions,
and only one patient experienced grade 1 peripheral oedema.
With regard to the relationship between liver function and toxi-
cities, the patients with liver dysfunction did not experience severe
toxicities (³ grade 3) more frequently compared to the patients
with normal liver function, although dose reduction was needed in
the two patients with liver dysfunction as a result of myelosup-
pression (Table 3). Toxicities in the 16 patients who received
docetaxel at the scheduled dose mirrored the findings in all 21
eligible patients.
DISCUSSION
Clinical trials to date have demonstrated that docetaxel has
significant and consistent anti-tumour activities in a variety of
solid tumours, including breast cancer, non-small-cell lung cancer
and ovarian cancer (Cerny et al, 1994; Francis et al, 1994; Adachi
et al, 1996; Dieras et al, 1996; Kunitoh et al, 1996). With regard to
PC, preclinical studies have shown docetaxel to be active in PC
models (Bissery et al, 1991), and two clinical trials of docetaxel at
100 mg m22 have demonstrated a promising anti-tumour activity
in PC (Rougie et al, 1994; Abbruzzese et al, 1995). In a French
trial, partial responses were achieved in six (20%) of 30 patients
with measurable liver metastases, with the median survival time of
212 days (Rougie et al, 1994). A trial reported from the USA
showed preliminary results of two partial responses (20%) in ten
assessable patients, with both responders showing improvement in
cancer-related pain and PS (Abbruzzese et al, 1995). These results
argued for the further evaluation of docetaxel in chemo-naive
patients with metastatic PC to define the true usefulness of this
agent.
The present study, in which 21 chemo-naive patients with
metastatic PC were treated with moderate-dose (60 mg m22)
docetaxel, failed to demonstrate an objective response against PC.
Although a significant number of patients with NC were noted
after docetaxel therapy, the duration of NC was brief, lasting a few
months in the majority of the patients. The median survival time of
118 days, which was comparable to most phase II trials of
metastatic PC, was much poorer than that in the French trail.
Furthermore, the clinical response such as improvement in PS
and/or pain was achieved in only a small portion of the patients.
With regard to toxicity, the severity of neutropenia, the dose-
limiting toxicity of this agent, was comparable between the current
study and earlier trials with 100 mg m22 (Cortes and Pazdur,
Table 2 Toxicity of docetaxel
Grade
Toxicity 1 2 3 4
Haematological toxicity
Per patient
Anaemia 8 3 2 0
Leucocytopenia 1 5 12 2
Neutropeniaa 027 1 1
Thrombocytopenia 3 1 1 0
Per course
Anaemia 14 4 2 0
Leucocytopenia 6 10 20 2
Neutropenia 3 3 17 16
Thrombocytopenia 3 1 1 0
Non-haematological toxicity
(per patient)
Gastrointestinal
Bilirubin 2 1 0 0
GOT 2 4 1 1
GPT 1 5 2 0
ALPb 0330
Anorexia 3 6 6 0
Nausea/vomiting 5 4 6 0
Diarrhoea 4 3 0 0
Fever 4 10 0 0
Skin rash 6 3 0 0
Alopecia 4 9 5 0
Sensory neuropathy 0 1 1 0
Malaise/fatigue 6 2 5 2
Othersc 4410
aOne death due to neutropenic sepsis. bALP: alkaline phosphatase. 
cIncludes proteinuria (n 5 1, grade 3), back pain (n 5 1, grade 2),
hyperventilation (n 5 1, grade 2), facial flush (n 5 1, grade 2), nail change
(n 5 1, grade 2), pruritus (n 5 1, grade 1), electrocardiography abnormality
(n 5 1, grade 1), headache (n 5 1, grade 1) and peripheral oedema
(n 5 1, grade 1).
Table 3 Toxicity of docetaxel with reference to liver function (per patient)
Liver function
Normal (n 5 6) Abnormal (n 5 15)
Grades Grades
3–4 (%) 3–4 (%)
Haematological toxicity
Anaemia 1 (17) 1 (7)
Leucocytopenia 6 (100) 8 (53)
Neutropenia 6 (100)a 12 (80)
Thrombocytopenia 1 (17) 0 (0)
Non-haematological toxicity
Gastrointestinal
Bilirubin 0 (0) 0 (0)
GOT 1 (17) 1 (7)
GPT 1 (17) 1 (7)
ALPb 2 (33) 1 (7)
Anorexia 2 (33) 4 (27)
Nausea/vomiting 2 (33) 4 (27)
Diarrhoea 0 (0) 0 (0)
Fever 0 (0) 0 (0)
Skin rash 0 (0) 0 (0)
Alopecia 2 (33) 3 (20)
Sensory neuropathy 0 (0) 1 (7)
Malaise/fatigue 3 (50) 4 (27)
Others 1 (17) 0 (0)
a One death due to neutropenic sepsis. bALP: alkaline phosphatase.442 S Okada et al
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1995). In fact, in our study, nearly 80% of the patients experienced
grade 3–4 neutropenia, and a considerable proportion of patients
developed a neutropenic fever. In contrast to haematological toxi-
city, the non-haematological toxicity in this study was relatively
different from that in earlier trials using a higher dosage (Cortes
and Pazdur, 1995). Despite the fact that no routine premeditation
was used, we observed no acute hypersensitivity reaction, and
peripheral oedema was seen infrequently. The differences might
be attributable to the differences in the dose per course and the
cumulative dosage.
The results of the present study, especially the anti-tumour
activities of docetaxel, are not consistent with those of the previous
phase II trials that used the higher dose (100 mg m22) of docetaxel
in advanced PC patients (Routine et al, 1994; Abbruzzese et al,
1995). The significantly lower dosage of the drug used here is the
most likely explanation for this inconsistency. A higher dose may
be clinically more effective, since the anti-tumour activity of
docetaxel probably depends on the dose (Fumoleau et al, 1993;
Adachi et al, 1996; Dieras et al, 1996). However, higher doses of
docetaxel could not be used given the results of phase I trails in
Japan (Taguchi et al, 1994). As described previously, a Japanese
phase I trial determined the MTD to be 70–90 mg m22 and the
recommended dose to be 60 mg m22 for further clinical trials. The
reason for the lower MTD in Japanese patients remains to be
elucidated. No racial difference was found in the elimination of
docetaxel (Bruno et al, 1995; Tanigawara et al, 1996).
In conclusion, docetaxel, at a dose of 60 mg m22 as a 1- to 2-h
intravenous infusion every 3–4 weeks, had no significant anti-
tumour activity, with considerable haematological toxicities in
chemo-naive metastatic PC patients. These data do not support the
practical use of docetaxel in Japanese patients with this disease.
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